ST
OCUL icon

Spot Trading’s Ocular Therapeutix OCUL Stock Holding History

Spot Trading’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-25,000
Closed -$172K – 3046
2016
Q3 		$172K Buy
+25,000
New +$152K ﹤0.01% 2169

Other funds holding OCUL

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Spot Trading's OCUL Position: Q4 2016 in Review

Spot Trading sold out of Ocular Therapeutix (OCUL) in Q4 2016, closing a stake of 6,600 shares — an estimated $45K sold.

Spot Trading first reported a position in OCUL in Q3 2016 and held it in 1 quarter. The position peaked at $45K in Q3 2016. 76 funds tracked by Wall St. Rank hold OCUL as of Q4 2016.

  • Spot Trading reported no remaining Ocular Therapeutix position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 6,600 Ocular Therapeutix shares in Q4 2016, an estimated $45K.
  • Spot Trading first reported a position in Ocular Therapeutix in Q3 2016 and held it in 1 quarter.
  • Spot Trading's Ocular Therapeutix position peaked at $45K in Q3 2016.
  • 76 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.